β-Amyloid (Aβ) oligomer signaling. The amyloid precursor protein (APP) is cleaved by β-secretase and γ-secretase to produce monomeric Aβ peptides that, in turn, assemble into toxic Aβ oligomers. β-Amyloid oligomers bind to cellular prion protein (PrPc), which likely signals via a putative transmembrane PrPccoreceptor. This binding mediates the inhibition of synaptic plasticity as measured by long-term potentiation and could be involved in other deleterious effects of Aβ oligomers, including synapse degeneration, rodent spatial memory impairments, and the neurodegeneration seen in human Alzheimer disease. Long-term potentiation may be suppressed by altering neurotransmission through N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors (AMPARs), as their distribution has been shown to be regulated by Aβ oligomers.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Nygaard HB, Strittmatter SM. Cellular Prion Protein Mediates the Toxicity of β-Amyloid Oligomers: Implications for Alzheimer Disease. Arch Neurol. 2009;66(11):1325–1328. doi:10.1001/archneurol.2009.223
HASSAN M.FATHALLAH-SHAYKHMD, PhD
Alzheimer disease (AD) is the most common cause of age-related dementia, affecting more than 25 million people worldwide. The accumulation of insoluble β-amyloid (Aβ) plaques in the brain has long been considered central to the pathogenesis of AD. However, recent evidence suggests that soluble oligomeric assemblies of Aβ may be of greater importance. β-Amyloid oligomers have been found to be potent synaptotoxins, but the mechanism by which they exert their action has remained elusive. Herein, we review the recently published finding that cellular prion protein (PrPc) is a high-affinity receptor for Aβ oligomers, mediating their toxic effects on synaptic plasticity. We further discuss the relationship between AD and PrPcand the potential clinical implications. Cellular prion protein may provide a novel target for therapeutic intervention in AD.
Alzheimer disease (AD) is a debilitating neurodegenerative disorder, estimated to affect at least 26.6 million people worldwide.1Over the next 40 years, this number is predicted to increase 4-fold,1stressing the need for more effective therapeutics. For many years, the leading hypothesis for the pathogenesis of AD has involved the toxic effects of a gradual buildup of β-amyloid (Aβ) plaques in the brain.2β-Amyloid is produced after sequential processing of the amyloid precursor protein (APP),2and increased levels of the Aβ1-42species are thought to be a key early event in AD.3A major criticism of the amyloid hypothesis has been that the burden of fibrillar Aβ, the insoluble species constituting plaques, correlates poorly with the degree of dementia4and brain atrophy,5and cognitively normal individuals may have significant plaque deposition at autopsy.6However, more recent findings have elucidated different assemblies of Aβ with varying degrees of toxic effects. β-Amyloid can exist as soluble monomers and oligomers, intermediate protofibrils, and insoluble fibrillar aggregates.7Of these, soluble Aβ oligomers are potent synaptotoxins,8and their concentration correlates with disease severity.9
Oligomers are small peptide polymers, and various toxic Aβ oligomers have been reported, ranging from dimers and trimers10to 100mers.11Nanomolar concentrations of Aβ oligomers strongly inhibit long-term potentiation (LTP),12,13a leading experimental model for the synaptic changes underlying learning and memory. Recent evidence also suggests that synapse degeneration, likely central to the memory impairment in AD,14first involves the single synaptic contact points between axons and dendrites found at dendritic spines.15Consistent with their role in neurodegeneration, Aβ oligomers cause significant decrease in dendritic spine density in cultured hippocampal neurons.15Behavioral assessments in rodents have confirmed these findings, complementing a growing number of in vitro investigations. β-Amyloid oligomers greatly impair spatial memory when administered to otherwise healthy rats.12,16
The concept of oligomeric Aβ synaptotoxins has helped strengthen the amyloid hypothesis. In transgenic mice, levels of specific Aβ oligomers closely match deficits in spatial memory,16and clinically the amount of soluble Aβ in the brain correlates well with the degree of dementia.9Moreover, Aβ oligomers isolated directly from human AD brains have been found to be equally toxic as synthetically derived Aβ.17Despite these recent breakthroughs, the mechanisms by which Aβ oligomers exert their action have not been well understood. The effects on neurons are rapid and specific, and together the accumulated data have suggested the presence of a high-affinity Aβ oligomer receptor. This putative receptor would likely be central to the pathogenesis of AD and provide an attractive target for therapeutic intervention. Herein, we review the recent finding that cellular prion protein (PrPc) is a high-affinity binding site for Aβ oligomers, mediating their potent inhibitory effects on synaptic plasticity.11We further discuss the association between PrPcand AD and the potential clinical relevance of these findings.
To detect Aβ oligomer binding sites, a biotin-tagged Aβ1-42peptide was first synthesized.11Biotin is frequently used as a molecular marker because of its extraordinarily high affinity for the protein avidin that, in turn, can be used for detection. The Aβ was oligomerized and applied to COS-7 cells expressing different complementary DNA (cDNA) obtained from an adult mouse brain library. At baseline, COS-7 cells show minimal binding of Aβ oligomers compared with hippocampal neurons, making these cells ideal for this type of screen. Biotin-Aβ oligomers potently bind hippocampal neurons, whereas monomeric Aβ does not, suggesting a necessary conformation of Aβ conferred by oligomerization.
Of 225 000 clones from the adult mouse cDNA library screened in the assay, 2 were found to bind biotin-Aβ oligomers. Both of these individual clones were subsequently shown to encode for full-length mouse PrPc. In addition to this unbiased genome-wide screen, a more specific library of known transmembrane proteins at lower stringency was assessed. As summarized in the Table, some were found to exhibit Aβ oligomer binding but with lesser affinity and selectivity than for PrPc. Several putative receptors for Aβ have previously been reported, including the receptor for advanced glycation end products,18α7 nicotinic acetylcholine receptor,19and tumor necrosis factor receptor 1.20In the binding assay reviewed herein, only PrPchad high affinity and high specificity for Aβ oligomers.
Cellular prion protein is a glycosylphosphatidylinositol-linked extracellular membrane protein of approximately 250 amino acids that is abundantly expressed in the nervous system.21It is likely best known to clinicians because of its role in human prion disease. Using PrPcdeletion mutants, the exact binding site of Aβ oligomers was mapped to the region of amino acids 95 to 110. This area is within the unstructured central domain of PrPc(amino acids 95-134), which has been implicated in neuronal toxic effects in vitro22and in extensive neurodegeneration in mice.23α-Secretase, which cleaves APP within the Aβ domain (precluding the toxic Aβ peptide), also cleaves PrPcwithin its unstructured central domain at amino acids 110 to 111.24Therefore, α-secretase may act to counter neurodegeneration by preventing the production of Aβ and by keeping potentially detrimental regions of PrPcin check. It is unknown whether cleavage of PrPcby α-secretase also affects Aβ oligomer binding.
To evaluate the functional role of the Aβ oligomer–×-PrPcinteraction, the effects of Aβ oligomers on LTP were measured in brain sections from mice in which the PrPcgene was knocked out (PRNP−/−) (176640). In wild-type hippocampal sections, a brief train of pulses in the theta frequency to Schaffer collateral fibers results in an increase in the excitatory postsynaptic potentials that can last for hours. This change in synaptic strength in response to a specific stimulus is believed to be a fundamental mechanism underlying learning and memory. When nanomolar concentrations of Aβ oligomers were applied to wild-type sections, LTP was strongly inhibited, as has been reported by numerous laboratories.10,13,17,20In contrast, no inhibitory effects on LTP were seen when the same Aβ preparation was applied to brain sections from PRNP−/− animals, suggesting that Aβ oligomer signaling is mediated through PrPc.11To confirm these findings, wild-type brain sections were pretreated with 6D11, a specific antibody to PrPcfound to block Aβ oligomer binding. When these pretreated sections were exposed to the Aβ solution, LTP was unaffected, further suggesting a critical role of PrPcin Aβ oligomer–induced synaptotoxic effects.
Because PrPcis an extracellular protein, downstream Aβ oligomer signaling is likely mediated via a putative PrPc-associated transmembrane coreceptor (Figure). This putative coreceptor may have a critical role in AD-related neurodegeneration and, once identified, could provide an additional potential therapeutic target.
For at least a decade, an indirect association between AD and PrPchas been lingering in the literature. Early interest was fueled mostly by the fact that AD and human prion disease involve aggregates of pathologic proteins in the brain25and that the amyloid precursor–like protein was reported to bind PrPc.26Recently, more specific evidence has emerged linking PrPcto AD. From a genetic perspective, interest has been growing in the PRNPmethionine/valine polymorphism (M129V) and its relationship to sporadic AD. Homozygosity at this codon, which is located within the unstructured central domain of PrPc, is associated with an increased risk of sporadic Creutzfeldt-Jakob disease.27Others have found that this genotype confers an increased risk for sporadic AD in certain populations.28Whether polymorphisms within the PRNPgene may affect Aβ oligomer binding to PrPcand alter susceptibility to AD is unknown, but it remains an intriguing possibility.
Cellular prion protein has also been reported to regulate APP processing by modulating β-secretase (BACE1) activity, but the results have been conflicting. Cells coexpressing APP and PrPchave a significant reduction in secreted Aβ compared with cells expressing APP alone.29The region of PrPcresponsible for this action was found to be in the N-terminus (amino acids 23-26), as no effects on BACE1 or Aβ levels were seen when this segment was removed.29However, overexpressing PrPcin transgenic APP mice caused a modest increase of Aβ plaques in the brain,30in contrast to the lowering effect of PrPcfound in vitro. It is unclear whether binding of Aβ oligomers to PrPcmight affect its proposed ability to regulate BACE1, setting up a potential feedback loop in response to Aβ levels, and this is an issue worth investigating further as the field moves forward.
In summary, we have reviewed the recent finding that PrPcfunctions as a high-affinity receptor to mediate the deleterious effects of Aβ oligomers on synaptic plasticity. Although much work remains to assess whether targeting PrPcor its putative coreceptor can be effective treatments in human AD, the potential is readily apparent. Cellular prior protein represents the first possible target in AD directly disrupting the signaling pathway of Aβ and might provide a more functional approach to relieving AD symptoms. Most important, modulating PrPcfunction does not seem to produce serious adverse effects, as PRNPknockout mice have minimal phenotypic changes and wild-type animals treated with PrPcantibodies do well. A large body of work on PrPcalready exists because of its role in prion diseases. This knowledge could greatly facilitate drug discovery and our understanding of the downstream mechanisms of the Aβ oligomer–×-PrPcinteraction.
Correspondence:Stephen M. Strittmatter, MD, PhD, Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, 295 Congress Ave, Boyer Center for Molecular Medicine 436, New Haven, CT 06536-0812 (firstname.lastname@example.org).
Accepted for Publication:May 13, 2009.
Author Contributions:Study concept and design: Nygaard and Strittmatter. Acquisition of data: Nygaard and Strittmatter. Analysis and interpretation of data: Nygaard and Strittmatter. Drafting of the manuscript: Nygaard and Strittmatter. Critical revision of the manuscript for important intellectual content: Nygaard and Strittmatter. Obtained funding: Strittmatter. Administrative, technical, and material support: Strittmatter. Study supervision: Strittmatter.
Financial Disclosure:None reported.
Funding/Support:This study was supported by grants from the Cure Alzheimer's Fund, National Institutes of Health, and Falk Medical Research Trust (Dr Strittmatter).